Sarah Holstein, M.D., Ph.D.
Associate Professor, Internal Medicine
Division of Oncology & Hematology
Academic office mailing address:
UNMC Oncology/Hematology Division
986840 Nebraska Medical Center
Omaha, NE 681980-6840
Main Academic Ph. 402-559-8500
New Patient Referral Ph. 402-559-5600
University of Iowa Carver College of Medicine, MD, PhD (2004)
University of Iowa Internal Medicine Resident (2004-2006)
University of Iowa Hematology/Oncology Fellow (2006-2010)
Clinical, translational, and basic science research in multiple myeloma with an emphasis on the development of novel therapeutic agents.
Dr. Holstein is a physician-scientist who specializes in the treatment of multiple myeloma and related plasma cell dyscrasias. Prior to joining the faculty at UNMC, Dr. Holstein served as a myeloma specialist at the Roswell Park Cancer Institute and the University of Iowa. Her laboratory is focused on gaining a better understanding of the pathophysiology of multiple myeloma and the development of novel therapeutic agents for multiple myeloma. Her laboratory research has received funding from such sources as the National Institutes of Health, the American Society of Hematology, and the PhRMA Foundation. Dr. Holstein is an active clinical investigator, and has been involved in clinical trials for patients with newly diagnosed myeloma, with relapsed/refractory disease, as well as in the post-transplant maintenance setting. She has written numerous peer-reviewed research articles as well as review articles and book chapters. She is a member of the Alliance Multiple Myeloma Committee and the NCCN Multiple Myeloma Panel.
Ammannagari, N., Celotto, K., Neppalli, V., Lee, K., and Holstein, S.A. Anaplastic multiple myeloma: an aggressive variant with poor response to novel therapies. Clinical Lymphoma, Myeloma & Leukemia, S2152-2650(16): 30113-6, 2016.
Foust, B.J., Allen, C., Holstein, S.A., and Wiemer, D.F. A new motif for inhibitors of geranylgeranyl diphosphate synthase. Bioorganic and Medicinal Chemistry, 24:3734-41, 2016.
Holstein, S.A., Richardson, P.G., Laubach, J.P., and McCarthy, P.L. Ask the Expert: Management of relapsed multiple myeloma after autologous stem cell transplant. Biology of Blood and Marrow Transplantation, 21:793-8, 2015.
Holstein, S.A., Ho, C.M., Balderman, S.R., and McCarthy, P.L. The future of post-autologous stem cell transplant therapy for multiple myeloma, Annals of Hematology & Oncology, 2 (9), 2015.
Holstein, S.A., Bigelow, J.C., Olson, R.D., Vestal, R.E., Walsh, G.M., and Hohl, R.J. A Phase I and pharmacokinetic study of 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors. Investigational New Drugs, 33: 594-602, 2015.
Dykstra, K.M., Allen, C., Born, E.J., Tong, H., and Holstein, S.A. Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. Oncotarget, 6: 41535-49, 2015.
Holstein, S.A., Liu, H., and McCarthy, P.L. Multiple Myeloma. In: Hematology/Oncology Clinics of North America, 28:1113-1129, 2014.
Holstein, S.A. The evolving tale of immunomodulatory drugs and cereblon. Clinical Pharmacology and Therapeutics, 96:538-541, 2014.
Born, E.J., Hartman, S.V., and Holstein, S.A. Targeting HSP90 and monoclonal protein trafficking modulates the unfolded protein response pathway, chaperone regulation, and apoptosis in myeloma cells. Blood Cancer Journal, 3:e167, 2013.
Holstein, S.A. and Hohl, R.J. Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells. Leukemia Research, 35: 551-9, 2011.
Additional Publications at PubMed.Gov: https://www.ncbi.nlm.nih.gov/pubmed